Prevalence and determinants of subretinal drusenoid deposits in patients' first-degree relatives.

Journal Information

Full Title: Graefes Arch Clin Exp Ophthalmol

Abbreviation: Graefes Arch Clin Exp Ophthalmol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethical approvalAll procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of the medical faculty of the University of Bonn and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors. This study was approved by the ethics committee of the medical faculty of the University of Bonn. Conflict of interestMatthias M. Mauschitz has received consulting fees from Biogen. Jan H. Terheyden has received support from Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue, Novartis, and Okko. Robert P. Finger has received grants from Novartis and Consulting fees from Bayer, Santen, Opthea, Novelion, ProQR, Oxford Innovation, Roche, Alimera, Santhera, Inositec, and Ellex. None of the aforementioned relations had any impact on this study. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Conflict of interest Matthias M. Mauschitz has received consulting fees from Biogen. Jan H. Terheyden has received support from Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue, Novartis, and Okko. Robert P. Finger has received grants from Novartis and Consulting fees from Bayer, Santen, Opthea, Novelion, ProQR, Oxford Innovation, Roche, Alimera, Santhera, Inositec, and Ellex. None of the aforementioned relations had any impact on this study. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL. Funding for genotyping was acquired via the Australian NHRMC synergy grant (#1181010) awarded to Robyn Guymer, Alice Pébay, Erica Fletcher, Melanie Bahlo, Zhichao Wu, and Brendan Ansell. The authors would like to express their gratitude."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025